Results 11 to 20 of about 5,641 (130)

Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study

Journal of Hepatocellular Carcinoma, 2021
Yi Yang, 1,* Yanzhao Zhou, 2, 3,* Xinyuan Zhang, 1,* Yujing Xin, 1 Yi Chen, 1, 4 Qingsheng Fan, 5 Xiao Li, 1 Xi Wei, 6 Qiang Li, 3 Xiang Zhou, 1 Jinxue Zhou 2 1Department of Interventional Therapy, National Cancer Center/National Clinical Research ...
Yang Y, Zhou Y, Zhang X, Xin Y, Chen Y, Fan Q, Li X, Wei X, Li Q, Zhou X, Zhou J   +10 more
doaj   +4 more sources

Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify. [PDF]

Br J Cancer, 2022
Abstract Background and aims The aMAP score is a model that predicts risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis. Its performance in a ‘real world’ surveillance setting has not yet been ascertained. Patients and methods We had access
Johnson PJ, Innes H, Hughes DM, Kalyuzhnyy A, Kumada T, Toyoda H.   +5 more
europepmc   +4 more sources

The aMAP Score is an Independent Risk Factor for Intermediate-stage Hepatocellular Carcinoma: A Large Retrospective Cohort Study. [PDF]

J Cancer, 2023
Background: A less effective nomogram for patients with intermediate-stage hepatocellular carcinoma (HCC) to predict overall survival (OS) is available. This study aimed to investigate the role of age-male-albumin-bilirubin-platelet (aMAP) scores in the prognosis of patients with intermediate-stage HCC and develop an aMAP score-based nomogram to ...
Chen Y, Shi Y, Lu L, Wang X, Lin Q, Lin Y, Wang R, Zhu H, Zheng P, Chen X.   +9 more
europepmc   +3 more sources

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis [PDF]

Journal of Hepatology, 2020
Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the HCC development for patients with chronic hepatitis.A total of 17,374 patients, comprising 10,578 treated Asian patients with chronic hepatitis B (CHB)
Rong Fan, George Papatheodoridis, Jian Sun, Hamish Innes, Hidenori Toyoda, Qing Xie, Shuyuan Mo, Vana Sypsa, Indra Neil Guha, Takashi Kumada, Junqi Niu, George Dalekos, Satoshi Yasuda, Eleanor Barnes, Jianqi Lian, Vithika Suri, Ramazan Idilman, Stephen T. Barclay, Xiaoguang Dou, Thomas Berg, Peter C. Hayes, John F. Flaherty, Yuanping Zhou, Zhengang Zhang, Maria Buti, Sharon J. Hutchinson, Yabing Guo, Jose Luis Calleja, Lanjia Lin, Longfeng Zhao, Yongpeng Chen, Harry L.A. Janssen, Chaonan Zhu, Lei Shi, Xiaoping Tang, Anuj Gaggar, Lai Wei, Jidong Jia, William L. Irving, Philip J. Johnson, Pietro Lampertico, Jinlin Hou   +41 more
openaire   +7 more sources

Validation of Noninvasive Markers for HCC Risk Stratification in 1389 Patients With Biopsy-proven NAFLD

Gastro Hep Advances, 2023
Background and Aims: Nonalcoholic fatty liver diseases (NAFLD) and nonalcoholic steatohepatitis (NASH) can cause hepatocellular carcinoma (HCC). We examined histological features and reported noninvasive markers/models for stratifying the risk of HCC ...
Hidenori Toyoda, Hideki Fujii, Michihiro Iwaki, Hideki Hayashi, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Sakura Yamamura, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Takumi Kawaguchi, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki, Satoshi Yasuda, Eiichi Tomita, Masato Yoneda, Norifumi Kawada, Akihiro Tokushige, Yoshihiro Kamada, Hirokazu Takahashi, Shinichiro Ueda, Shinichi Aishima, Yoshio Sumida, Atsushi Nakajima, Takeshi Okanoue   +33 more
doaj   +1 more source

Usefulness of aMAP Risk Score for Predicting Recurrence after Curative Treatment for Hepatocellular Carcinoma within Milan Criteria

Oncology, 2023
Introduction: The aMAP score is a prediction model for hepatocellular carcinoma (HCC) risk in chronic hepatitis patients. This study was conducted to elucidate the utility of this model for predicting initial recurrence of HCC in patients within the Milan criteria after undergoing curative treatment.
Ohama, Hideko, Hiraoka, Atsushi, Tada, Fujimasa, Kato, Kanako, Fukunishi, Yoshiko, Yanagihara, Emi, Kato, Masaya, Saneto, Hironobu, Izumoto, Hirofumi, Ueki, Hidetaro, Yoshino, Takeaki, Kitahata, Shogo, Kawamura, Tomoe, Kuroda, Taira, Suga, Yoshifumi, Miyata, Hideki, Hirooka, Masashi, Abe, Masanori, Matsuura, Bunzo, Ninomiya, Tomoyuki, Hiasa, Yoichi   +20 more
openaire   +2 more sources

IDDF2021-ABS-0137 The aMAP score predicts risk of hepatocellular carcinoma development in patients with alcohol-related cirrhosis [PDF]

Clinical Hepatology, 2021
Background The aMAP score (derived from age, male sex, albumin and platelet count) was recently devised to predict hepatocellular carcinoma (HCC) development. It was shown to have excellent performance irrespective of aetiology and ethnicity. Only one cohort of non-viral hepatitis patients (Japanese with mostly non-alcoholic fatty liver disease) was ...
Ken Liu, Steven Masson, Waleed Fateen, Guruprasad Aithal, Terry CF Yip, Devanshi Seth   +5 more
openaire   +1 more source

Non-Invasive Prediction Scores for Hepatitis B Virus- and Hepatitis D Virus-Infected Patients—A Cohort from the North-Eastern Part of Romania

Microorganisms, 2023
Approximately 62–72 million people are infected worldwide with HDV. Patients with chronic hepatitis D (CHD) have a higher risk of developing cirrhosis or hepatocellular carcinoma (HCC) and an increased mortality rate compared to those with chronic ...
Laura Iulia Grecu, Camelia Sultana, Mariana Pavel-Tanasa, Simona Maria Ruta, Mihaela Chivu-Economescu, Lilia Matei, Ramona Gabriela Ursu, Elena Iftimi, Luminita Smaranda Iancu   +8 more
doaj   +1 more source

Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection

JHEP Reports, 2021
Background & Aims: Hepatocellular carcinoma (HCC) prediction models can inform clinical decisions about HCC screening provided their predictions are robust. We conducted an external validation of 6 HCC prediction models for UK patients with cirrhosis
Hamish Innes, Peter Jepsen, Scott McDonald, John Dillon, Victoria Hamill, Alan Yeung, Jennifer Benselin, April Went, Andrew Fraser, Andrew Bathgate, M. Azim Ansari, Stephen T. Barclay, David Goldberg, Peter C. Hayes, Philip Johnson, Eleanor Barnes, William Irving, Sharon Hutchinson, Indra Neil Guha   +18 more
doaj   +1 more source

Validation of the aMAP score to predict hepatocellular carcinoma development in a cohort of alcohol‐related cirrhosis patients

Liver Cancer International, 2022
AbstractBackground and AimsThe aMAP score was recently devised to predict hepatocellular carcinoma (HCC) development. However, its performance was not tested in alcohol‐related cirrhosis (ALC). We aimed to validate the aMAP score in a cohort of ALC patients.MethodStudy participants with ALC from a prior genome‐wide association study were included.
Ken Liu, Terry C. F. Yip, Steven Masson, Waleed Fateen, Tae‐Hwi Schwantes‐An, Geoffrey W. McCaughan, Timothy R. Morgan, Guruprasad P. Aithal, Devanshi Seth   +8 more
openaire   +1 more source